Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
Karyopharm Therapeutics Q1 Earnings Call Highlights MarketBeat - Thu May 14, 12:09PM CDT

Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial...

KPTI : 8.16 (+1.24%)
Karyopharm Therapeutics: Q1 Earnings Snapshot AP - Thu May 14, 6:40AM CDT

Karyopharm Therapeutics: Q1 Earnings Snapshot

KPTI : 8.16 (+1.24%)
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire - Thu May 14, 6:30AM CDT

– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 –

KPTI : 8.16 (+1.24%)
Karyopharm to Participate at Upcoming Investor Conferences PR Newswire - Tue May 12, 6:30AM CDT

NEWTON, Mass. , May 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's...

KPTI : 8.16 (+1.24%)
Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 PR Newswire - Thu May 7, 6:30AM CDT

-- Conference Call Scheduled for Thursday, May 14, 2026, at 8:00 a.m. ET --

KPTI : 8.16 (+1.24%)
Karyopharm Announces $30 Million Private Placement with RA Capital PR Newswire - Tue Mar 24, 6:01AM CDT

NEWTON, Mass. , March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has...

KPTI : 8.16 (+1.24%)
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction PR Newswire - Tue Mar 24, 6:00AM CDT

– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS –

KPTI : 8.16 (+1.24%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Mon Mar 2, 3:05PM CST

NEWTON, Mass. , March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 8.16 (+1.24%)
Karyopharm Therapeutics: Q4 Earnings Snapshot AP - Thu Feb 12, 6:47AM CST

Karyopharm Therapeutics: Q4 Earnings Snapshot

KPTI : 8.16 (+1.24%)
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress PR Newswire - Thu Feb 12, 6:30AM CST

–  Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –

KPTI : 8.16 (+1.24%)

Barchart Exclusives

Berkshire Hathaway Buys Macy’s After 60 Years Away From Department Stores. M Stock Offers Real Estate, Dividends, and an Interesting Twist. Barchart - Mon May 25, 6:30PM CDT
Berkshire Hathaway’s unexpected return to the department store sector with a new stake in Macy’s suggests it may see overlooked value in the retailer. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.